%0 Journal Article
%A Piot, Ines
%A Schweyer, Kerstin
%A Respondek, Gesine
%A Stamelou, Maria
%A Sckopke, Philipp
%A Schenk, Thomas
%A Goetz, Christopher G
%A Stebbins, Glenn T
%A Höglinger, Günter
%A Gasser, Thomas
%A Hermann, Andreas
%A Höglinger, Günter
%A Höllerhage, Matthias
%A Kimmich, Okka
%A Klockgether, Thomas
%A Levin, Johannes
%A Machetanz, Gerrit
%A Osterrath, Antje
%A Palleis, Carla
%A Prudlo, Johannes
%A Spottke, Annika
%A Berg, Daniela
%A Bürk, Katrin
%A Claßen, Joseph
%A Eggers, Carsten
%A Greuel, Andrea
%A Grimm, Max-Joseph
%A Hermann, Lennard
%A Iankova, Vassilena
%A Jahn, Klaus
%A Jost, Wolfgang
%A Klietz, Martin
%A Kühn, Andrea
%A Marxreiter, Franz
%A Paschen, Steffen
%A Poetter-Nerger, Monika
%A Preisl, Marie-Therese
%A Prilop, Lisa
%A Tönges, Lars
%A Trenkwalder, Claudia
%A Warnecke, Tobias
%A Wegner, Florian
%A Winkler, Jürgen
%A Antonini, Angelo
%A P, Kailash P
%A L, Adam L
%A Colosimo, Carlo
%A Compta, Yaroslau
%A Corvol, Jean-Christophe
%A I, Lawrence I
%A Höglinger, Günter U
%A E, Anthony E
%A Litvan, Irene
%A R, Huw R
%A Nilsson, Christer
%A Pantelyat, Alexander
%A Respondek, Gesine
%A Stamelou, Maria
%T The Progressive Supranuclear Palsy Clinical Deficits Scale.
%J Movement disorders
%V 35
%N 4
%@ 0885-3185
%C New York, NY
%I Wiley
%M DZNE-2020-00406
%P 650-661
%D 2020
%X There is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes.To develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes.The Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait </td><td width="150">
%X  balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts).Cognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62
%K Disease Progression
%K Female
%K Fingers
%K Humans
%K Male
%K Motor Skills
%K Reproducibility of Results
%K Supranuclear Palsy, Progressive: diagnosis
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31951049
%R 10.1002/mds.27964
%U https://pub.dzne.de/record/145046